A two-year partnership with Ultrahuman aims to connect clinical biomarkers and wearable data, bringing aging assessment into ...

GPX4-targeting therapy reduces epigenetic age markers and circulating inflammation, raising questions about effects beyond ...

Ascensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well ...

A new partnership is combining a blood test, a cognitive app and national infrastructure to cut Britain’s years-long ...

MUST’s RETRO-EPIGERNA team won $1 million and a place in the $81 million finals, though key trial details remain undisclosed.

Neither the FDA nor EMA recognizes aging as an indication – but the drafts, the precedent and the people on record are ...

Oxford biotech secures $47 million to scale cell-based mRNA manufacturing, with an eye on therapies that require repeated ...

At LIC 2026, investors, scientists and founders examined what survives the journey from longevity hypothesis to human ...

First-in-human ER-100 data support dose escalation, with early visual-field signals in two of three glaucoma patients.

At ARDD 2026, senior FDA officials sketch how a therapy targeting aging might one day reach approval, revealing that ...

Deep Longevity’s new US telehealth platform, Accrua, ties treatment plans to a blood-based aging score and re-tests every ...

The Austin-based microbiome testing company raised a $33M Series B, and adults now outnumber babies in its testing volume.